ABSTRACT
Introduction 655 Clinical features 655 Morphologic features 656 Immunophenotype 657 Genetic/molecular findings 657 Other neoplasms positive for ALK protein 658 Gene expression profiling of anaplastic large cell lymphomas 659 Experimental studies, transgenic mouse models and 659
ALK inhibitors
Experimental analysis of the transforming properties 659 of X-ALK fusion proteins
Transgenic models 660 ALK tyrosine kinase inhibitors 660 Clinical course and prognostic factors 660 Key points 661 References 661
In 1985, Stein and coworkers1 recognized a subgroup of tumors with large-sized cells showing bizarre morphologic features, prominent sinusoidal invasion and expressing the Ki-1 antigen (now referred to as the CD30 molecule). These tumors were designated as ‘Ki-1 lymphoma’.1
